Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Name: Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Published: 2025
License: Public Domain

Revolution Medicines, Inc. · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

kras pancreatic-cancer pancreatic-ductal-adenocarcinoma ras

pancreatic cancer, pdac, pdac - pancreatic ductal adenocarcinoma, resectable pancreatic ductal adenocarcinoma (pdac), resected pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, ras, kras, nras, hras, ras wild-type, rasolute

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 835494
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.